1713 ET - Gilead is poised to build on expanding demand for its HIV products. The company said in its 4Q earnings report that it plans to launch another HIV treatment after sales in the segment climbed 16% in the past quarter and was the primary driver of Gilead's overall sales growth. Higher demand, elevated average realized price and favorably inventory dynamics are making HIV a profitable segment right now, and helping the biopharma firm offset losses from its dwindling Covid product. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
February 11, 2025 17:13 ET (22:13 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.